Sherwin-Williams Shareholders Elect New Director prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Evotec accelerates access to biologic therapeutics with initiation of manufacturing facility in Toulouse
DGAP-News: Evotec SE / Key word(s): Miscellaneous
20.04.2021 / 07:30
J.POD
(R) 2 EU BIOMANUFACTURING WILL PLAY A KEY ROLE IN ADDRESSING THE NEED FOR THERAPEUTIC ANTIBODIES, INCLUDING THOSE RELATED TO INFECTIOUS DISEASES SUCH AS COVID-19
EVOTEC WILL BE SUPPORTED BY THE FRENCH GOVERNMENT AS WELL AS THE OCCITANIE REGION, BPIFRANCE, THE HAUTE-GARONNE PREFECTURE AND TOULOUSE MÉTROPOLE
CONSTRUCTION OF THE J.POD
Hamburg, Germany, 20 April 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the Company has initiated the construction of its J.POD
(R) 2 EU biologics manufacturing facility at Evotec s Campus Curie in Toulouse, France. J.POD
Evotec Accelerates Access to Biologic Therapeutics with Initiation of Manufacturing Facility in Toulouse streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801
DGAP-News: Evotec SE / Key word(s): Miscellaneous
19.04.2021 / 08:31
The issuer is solely responsible for the content of this announcement.
EVOTEC GRANTS KAZIA THERAPEUTICS AN EXCLUSIVE WORLDWIDE LICENSE FOR DEVELOPMENT AND COMMERCIALISATION OF ONCOLOGY ASSET EVT801
KAZIA INTENDS TO INITIATE A PHASE I CLINICAL TRIAL OF EVT801 MANAGED BY EVOTEC
EVOTEC WILL PROVIDE CHEMISTRY, MANUFACTURING AND CONTROLS ( CMC )
EVOTEC RECEIVES A SMALL UPFRONT PAYMENT AS WELL AS RESEARCH FUNDING TO DEVELOP A BIOMARKER, AND IS ELIGIBLE TO RECEIVE CLINICAL AND COMMERCIAL MILESTONES AS WELL AS TIERED ROYALTIES ON THE NET SALES
Evotec AG: Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801
KAZIA INTENDS TO INITIATE A PHASE I CLINICAL TRIAL OF EVT801 MANAGED BY EVOTEC
EVOTEC WILL PROVIDE CHEMISTRY, MANUFACTURING AND CONTROLS ( CMC )
EVOTEC RECEIVES A SMALL UPFRONT PAYMENT AS WELL AS RESEARCH FUNDING TO DEVELOP A BIOMARKER, AND IS ELIGIBLE TO RECEIVE CLINICAL AND COMMERCIAL MILESTONES AS WELL AS TIERED ROYALTIES ON THE NET SALES
HAMBURG, GERMANY / ACCESSWIRE / April 19, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has entered into both a licensing and master service agreement with Kazia Therapeutics Limited ( Kazia , ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company. Under the contract, Evotec will grant Kazia an exclusive worldwide license for research, development and commercialisation of Evotec s oncology project EVT801.